BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19626933)

  • 1. [Bone remodeling: new therapeutic approaches].
    Ferrari S
    Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to the treatment of osteoporosis.
    Silva BC; Bilezikian JP
    Annu Rev Med; 2011; 62():307-22. PubMed ID: 21054170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
    Quemerais-Durieu MA; Kerlan V; Chabre O
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis: now and the future.
    Rachner TD; Khosla S; Hofbauer LC
    Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments in the pharmacotherapeutic management of osteoporosis.
    Close P; Neuprez A; Reginster JY
    Expert Opin Pharmacother; 2006 Aug; 7(12):1603-15. PubMed ID: 16872263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Secondary osteoporosis UPDATE. Treatment of male osteoporosis. Testosterone replacement therapy etc].
    Kawate H; Takayanagi R
    Clin Calcium; 2010 May; 20(5):744-51. PubMed ID: 20445286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.
    Sims NA; Ng KW
    Curr Osteoporos Rep; 2014 Mar; 12(1):98-106. PubMed ID: 24477416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Parathyroid hormone for osteroporsis: why and who to treat?].
    Ferrari S; Rizzoli R
    Rev Med Suisse; 2005 Oct; 1(35):2272-4, 2276-7. PubMed ID: 16268450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-induced osteoporosis].
    Tanaka Y
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():394-8. PubMed ID: 18074570
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis].
    Kaneko K; Kawai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):138-48. PubMed ID: 21720102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.